TrialBritish journal of cancer2026

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Katrin M Sjoquist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.